The costs of outpatient parenteral antibiotic therapy are outweighed by the benefits to all involved: provider, payer, patient, and society. Simple comparisons of inpatient and outpatient charges are not a true measure of costs. Recent in-depth cost-benefit analyses reveal a significant saving when indirect benefits, such as increased productivity and quality of life, are included. Even so, financial issues remain to be addressed.
No takes yet. Share an insight, caveat, or question.
Gary Milkovich (1993) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: